Retatrutide: Investigational Triple Hormone Receptor Agonist
Retatrutide represents a significant milestone in metabolic research. Unlike earlier incretin-based molecules that target one or two receptors, retatrutide is a “triple agonist,” engineered to simultaneously activate receptors for GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon.
As of 2026, retatrutide remains an investigational molecule, evaluated in Phase 3 clinical programs (e.g. TRIUMPH, TRANSCEND-T2D). It is not approved for public use or medical prescription.
Mechanism of action: the “triple-G” synergy
- GIP receptor agonism: complements GLP-1 in studies of insulin secretion and lipid metabolism.
- GLP-1 receptor agonism: stimulates satiety signaling and slows gastric emptying in research models.
- Glucagon receptor agonism: the distinctive third axis — studied for increasing energy expenditure and mobilizing stored fat.
Current research status
- Clinical trials: extensive Phase 3 trials evaluate obesity, type 2 diabetes, osteoarthritis, sleep apnea, and cardiovascular/renal outcomes.
- Regulatory status: not approved by Health Canada or the FDA; no DIN or authorized therapeutic indication.
- Availability: for legitimate laboratory research only. Always verify source purity and certificates of analysis.
Research-grade sourcing
For valid data, research requires authenticated, high-purity compounds. Our Retatrutide is independently third-party tested to over 99% purity with a certificate of analysis on every lot. Browse related metabolic research peptides: Semaglutide, Tirzepatide.
This guide is part of our Peptides Canada research hub — explore the full library of compound guides.
Note: This information is for educational research purposes only. Retatrutide is an investigational compound, not authorized for human consumption, sale, or medical use outside formal clinical trials. It is a research chemical intended strictly for laboratory and research use.